GlassScriptPhysician profile
Raza Hassan
NPI 1912929282
$6,179.41
in general payments reported to CMS, 2019-2025
27 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $811 · 2021: $854 · 2022: $1,057 · 2023: $1,139 · 2024: $679 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,569.38 | 2019-2025 | Merlin@Home, Aveir, Accent |
| Novartis Pharmaceuticals Corporation | $779.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $764.30 | 2019-2024 | Xarelto |
| Amgen INC. | $652.65 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.47 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $333.76 | 2021-2023 | Watchman Flx, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $285.86 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $192.06 | 2021-2023 | Verquvo |
| Cvrx, INC. | $186.66 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $184.84 | 2019-2023 | |
| Philips North America LLC | $166.77 | 2022-2025 | (5091) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.43 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $97.28 | 2020-2025 | Lokelma |
| Astellas Pharma US INC | $61.15 | 2019-2021 | |
| Medtronic, INC. | $51.84 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $51.34 | 2019-2020 | |
| Esperion Therapeutics, INC. | $50.99 | 2020-2025 | Nexletol |
| Lundbeck LLC | $39.56 | 2019 | |
| Impulse Dynamics (USA) INC. | $31.53 | 2025 | Optimizer |
| Gilead Sciences, INC. | $31.05 | 2023 | |
| Kestra Medical Technology Services, INC. | $28.17 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $23.19 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $20.40 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.39 | 2024 | Onpattro |
| Scpharmaceuticals INC. | $18.88 | 2025 | |
| Arbor Pharmaceuticals, INC. | $16.17 | 2019 | |
| Terumo Medical Corporation | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.